Research programme: anti-CD137 monoclonal antibodies - Bristol-Myers Squibb

Drug Profile

Research programme: anti-CD137 monoclonal antibodies - Bristol-Myers Squibb

Alternative Names: 10C7; 10C7 Antibody; Anti-4-1BB monoclonal antibodies; BMS 469492; BMS 554271

Latest Information Update: 23 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 23 Feb 2010 Preclinical development is ongoing
  • 15 Jan 2008 Preclinical development is ongoing
  • 27 Apr 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top